👩🍳 How we use AI at Tech in Asia, thoughtfully and responsibly.
🧔♂️ A friendly human may check it before it goes live. More news here
🧔♂️ A friendly human may check it before it goes live. More news here
Accel in talks to back Indian pharmacy startup Plazza
Plazza, a Bengaluru-based e-pharmacy startup founded in 2024 by former Zomato executive Aman Priyadarshi, is in talks to raise US$12 million to US$15 million.
The round is expected from Accel, Nexus Venture Partners, and Elevation Capital at a valuation of about US$45 million to US$50 million, said people familiar with the matter.
Existing backers including All In Capital and Better Capital are also expected to join the round, which would be Plazza’s second after a US$1.4 million raise in September 2025.
The company plans to use the funds to expand from two stores in Bengaluru to about 20 by year-end, one person said.
🔗 Source: The Economic Times
🧠 Food for thought
Implications, context, and why it matters.
Plazza is building a franchise network beyond dark stores
- Some rivals rely on dark stores for fast delivery. Plazza instead runs a franchise model called “Lifestores” 1.
- Lifestores start as existing pharmacies that convert into Plazza-run outlets through a franchise deal. Plazza helps with inventory management, software installation, staff hiring, and customer acquisition through its platform. It splits profits with partner stores 1.
- The approach comes from co-founder Aniruddha Sen’s earlier work at Kenko. The founders said limited control over service quality held back growth 1.
- Plazza puts its average order value at 700 Indian rupees 1.
Plazza’s funding talks run into an unfinished e-pharmacy rulebook
- India’s draft e-pharmacy rules from 2018 still are not final. Startups and platforms therefore work without a settled rulebook 2.
- Industry bodies warn that a push for speed can weaken prescription checks for controlled substances. Mint cited misuse risks involving Schedule H drugs, which are prescription-only medicines in India, such as pregabalin 2.
- Mint cited “ghost prescriptions” that can be forged or reused. In February 2023, the Central Drugs Standard Control Organisation (CDSCO), India’s national drug regulator, sent show-cause notices to 20 e-pharmacies. The list included Tata 1mg, Amazon, Flipkart, and Netmeds for allegedly selling drugs without valid licenses or prescriptions 2.
- More capital can push faster delivery, which can draw more regulatory attention. The cited source does not establish any specific “overnight” shutdown risk 2.




